SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

SEGMENT AND GEOGRAPHIC INFORMATION

The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.

•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.

•The Tissue Technologies segment includes such offerings as skin and wound repair, plastics & surgical reconstruction products, bone grafts, and nerve and tendon repair products. In conjunction with the sale of the Extremity Orthopedics business, the Company rebranded the Orthopedics and Tissue Technologies segment as Tissue Technologies in the first quarter of 2021.

The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the years ended December 31, 2021, 2020 and 2019 are as follows:

	Years Ended December 31,
Dollars in thousands	2021		2020		2019
Segment Net Sales
Codman Specialty Surgical	$	1,025,232	$	894,831	$	996,206
Tissue Technologies	517,216		477,037		521,351
Total revenues	$	1,542,448	$	1,371,868	$	1,517,557
Segment Profit
Codman Specialty Surgical	$	439,471	$	356,657	$	395,019
Tissue Technologies	228,199		159,630		144,638
Segment profit	667,670		516,287		539,657
Amortization	(16,914)		(27,757)		(27,028)
Corporate and other	(453,526)		(337,160)		(418,869)
Operating income	$	197,230	$	151,370	$	93,760

The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenue to geographic areas based on the location of the customer. Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:

Dollars in thousands	United States(1)		Europe		Asia Pacific		Rest of the World		Consolidated
Total revenue, net:
2021	$	1,089,526	$	191,327	$	182,034	$	79,561	$	1,542,448
2020	971,975		172,689		157,174		70,030		1,371,868
2019	1,077,379		197,468		157,391		85,319		1,517,557
Total long-lived assets:
2021	$	339,535	$	55,026	$	11,289	$	6,836	$	412,686
2020	324,893		38,812		13,121		5,577		382,403

(1) Includes long-lived assets in Puerto Rico.